Product Name: SIK (264-278)
Product Number: PE-01AYW99
| Size: | 200 µg | Price: | 51.00 | |
| 1 mg | $US | 102.00 | ||
| 5 mg | 224.00 |
Peptide Name: SIK (264-278)
Product Use: Services as a blocking peptide for use with the SNF1lK-2 rabbit polyclonal antibody (Cat. No.: AB-NK251-2) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic domain last alpha-chain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CARRITIAQIRQHRWM
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2038.5 Da
Peptide Purity Percent after Synthesis and Purification: >95
Product Use: Services as a blocking peptide for use with the SNF1lK-2 rabbit polyclonal antibody (Cat. No.: AB-NK251-2) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic domain last alpha-chain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CARRITIAQIRQHRWM
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2038.5 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: SIK pan-specific antibody (Cat. No.: AB-NK251-2)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: SIK pan-specific antibody (Cat. No.: AB-NK251-2)
Scientific Background: SIK (SNF1LK) is a protein-serine/threonine kinase of the CAMK group and CAMKL family. It can mediate gluconeogenesis, lipogenesis, cell cycle regulation, muscle differentiation, muscle growth, and tumour suppression. Substrates of SIK can include SREBF1, HDAC5, PPME1, TORC1/CRTC1, HDAC4, and TORC2/CRTC2. Phosphorylation at S186 increases phosphotransferase activity and induces interaction with 14-3-3. It is also activated by phosphorylation on T182 by STK11 in complex with STE20-related adapter-alpha (STRAD alpha) pseudo kinase and CAB39. SIK may be a tumour requiring protein (TRP). The loss of SIK1 has been correlated with poor prognosis for individuals suffering from breast cancer. Kinase phosphotransferase activity can be decreased without affecting autophosphorylation levels of SIK through either a S135A, or a S209A, or a S248A mutation. LKB1/LKB1-mediated phosphorylation and activation of SIK can be inhibited through a T182A mutation in SIK. Partial inhibition of phosphorylation and of kinase phosphotransferase activity has been observed with the S186A/D/C/G mutation. Abrogation of autophosphorylation and kinase phosphotransferase activity can occur with a S186T mutation.
© Kinexus Bioinformatics Corporation 2017